Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Lea, A. Metryka, F. Facchinetti, M. Civelli, G. Villetti, D. Singh (Manchester, United Kingdom; Parma, Italy). Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue. Eur Respir J 2014; 44: Suppl. 58, 4861

Member's Comments

No comment yet.

Related content which might interest you: Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 COPD airway epithelium secretion attracts and activates neutrophils Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015